IRLAB Therapeutics AB
STO:IRLAB A
IRLAB Therapeutics AB
STO:IRLAB A
Price:
1.55
SEK
1.97%
Market Closed
Market Cap:
kr131.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
IRLAB Therapeutics AB
STO:IRLAB A
|
SE |
Multiples-Based Value
The Multiples-Based Value of one
IRLAB A
stock under the Base Case scenario is
3.74
SEK.
Compared to the current market price of 1.55 SEK,
IRLAB Therapeutics AB
is
Undervalued by 59%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IRLAB A
Multiples-Based Value
Base Case
3.74
SEK
Undervaluation 59%
Multiples Across Competitors
IRLAB A Competitors Multiples
IRLAB Therapeutics AB Competitors
IRLAB Therapeutics AB Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
|
IRLAB Therapeutics AB
STO:IRLAB A
|
131.7m SEK | 2.3 | -1.2 | -0.8 | -0.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
865.7B USD | 13 | 41.1 | 27.7 | 29.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
577.7B USD | 6.1 | 21.5 | 14.9 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.4 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD | 4.5 | 16.1 | 10 | 12.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218.1B GBP | 4.9 | 28.1 | 15.6 | 22 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.5B CHF | 5.2 | 21.1 | 13.1 | 16.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.1B USD | 2.5 | 20.2 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.6B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
